1. Home
  2. CCCC vs OXSQ Comparison

CCCC vs OXSQ Comparison

Compare CCCC & OXSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCCC
  • OXSQ
  • Stock Information
  • Founded
  • CCCC 2015
  • OXSQ 2003
  • Country
  • CCCC United States
  • OXSQ United States
  • Employees
  • CCCC N/A
  • OXSQ N/A
  • Industry
  • CCCC Biotechnology: Pharmaceutical Preparations
  • OXSQ Blank Checks
  • Sector
  • CCCC Health Care
  • OXSQ Finance
  • Exchange
  • CCCC Nasdaq
  • OXSQ Nasdaq
  • Market Cap
  • CCCC 175.1M
  • OXSQ 150.6M
  • IPO Year
  • CCCC 2020
  • OXSQ N/A
  • Fundamental
  • Price
  • CCCC $2.23
  • OXSQ $1.68
  • Analyst Decision
  • CCCC Strong Buy
  • OXSQ
  • Analyst Count
  • CCCC 4
  • OXSQ 0
  • Target Price
  • CCCC $8.50
  • OXSQ N/A
  • AVG Volume (30 Days)
  • CCCC 1.8M
  • OXSQ 1.1M
  • Earning Date
  • CCCC 10-30-2025
  • OXSQ 11-04-2025
  • Dividend Yield
  • CCCC N/A
  • OXSQ 25.00%
  • EPS Growth
  • CCCC N/A
  • OXSQ N/A
  • EPS
  • CCCC N/A
  • OXSQ N/A
  • Revenue
  • CCCC $34,240,000.00
  • OXSQ $40,243,556.00
  • Revenue This Year
  • CCCC N/A
  • OXSQ N/A
  • Revenue Next Year
  • CCCC N/A
  • OXSQ N/A
  • P/E Ratio
  • CCCC N/A
  • OXSQ N/A
  • Revenue Growth
  • CCCC 16.55
  • OXSQ N/A
  • 52 Week Low
  • CCCC $1.09
  • OXSQ $1.62
  • 52 Week High
  • CCCC $7.14
  • OXSQ $2.99
  • Technical
  • Relative Strength Index (RSI)
  • CCCC 38.70
  • OXSQ 12.74
  • Support Level
  • CCCC $3.21
  • OXSQ $1.62
  • Resistance Level
  • CCCC $3.43
  • OXSQ $2.20
  • Average True Range (ATR)
  • CCCC 0.30
  • OXSQ 0.07
  • MACD
  • CCCC -0.12
  • OXSQ -0.05
  • Stochastic Oscillator
  • CCCC 6.58
  • OXSQ 10.00

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

About OXSQ Oxford Square Capital Corp.

Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.

Share on Social Networks: